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Obesity is a major health issue in developed as well as developing countries. While obesity is associated with relatively good health
status in some individuals, it may become a health issue for others. Obesity in the context of inflammation has been studied
extensively. However, whether obesity in its various forms has the same adverse eﬀects is a matter of debate and requires further
research. During its natural history, metabolically healthy obesity (MHO) converts into metabolically unhealthy obesity (MUHO).
What causes this transition to occur and what is the role of obesity-related mediators of inflammation during this transition is
discussed in this paper.
1. Background
Obesity and its associated comorbidities have become major
health problems in the world [1]. The association between
obesity and the development of major complications in
acute pancreatitis [2], fatty liver diseases [3], vascular
inflammation and coronary heart disease [4, 5], chronic
obstructive pulmonary disease [6], risk of cerebral ischemia
and brain injury [7], atherosclerotic vascular disease and
myocardial infarction [8], and cancers [9–11] are strongly
linked to chronic inflammation (Figure 1). In particular,
insulin resistance, a direct or indirect result of obesity, is
characterized by a chronic state of subclinical inflamma-
tion [12] and inactivation of a number of inflammatory
mediators [13–15]. Elevated serum concentrations of C-
reactive protein [16], interleukin IL-6, IL-8, and tumor
necrosis factor (TNF)-α are observed in obese individuals
with elevated insulin resistance [17].
Interestingly, however, a life course perspective on obesity
recognizes that obese individuals are not a homogeneous
group, but highly heterogeneous, given individual diﬀerences
in terms of health status and functional ability among
obese individuals. A substantially large number of the adult
obese population is reported to remain relatively “metabol-
ically healthy” obese (MHO) [18]. Unlike “metabolically
unhealthy” obese (MUHO) individuals, MHO individuals
demonstrate an absence of impaired glucose tolerance, dys-
lipidemia, hyperuricemia, and hypertension [19]. Whether
these represent valid subtypes of obesity, and whether obesity
is an independent predictor of metabolic outcomes or
mediated by inflammatory status is still unclear. Research
so far has not elucidated the factor(s) responsible for
causing obesity to becomemetabolically unhealthy. These are
important questions since a lifetime burden of obesity and
its consequences, and a clear understanding of the metabolic
transition process carries a host of clinical and public health
implications.
2. The Disease Burden of Obesity
Obesity is a condition of energy imbalance between intake
and expenditure. When an organism encounters food excess,
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Figure 1: The relationship between obesity and comorbidities. The consequences of obesity are depicted and include the immunological
component (T cells and macrophages) that drives inflammation together with adipocytes. The associated pathologies mentioned have
been associated with increased levels of inflammatory markers that are also increased in obesity. Although it is not clear which one is
the consequence and which one is the cause both are associated to higher clinical vulnerability. MIP-1α: macrophage inflammatory protein-
1 alpha; MCP-1: monocyte chemotactic protein-1; IP-10: interferon gamma-induced protein 10; SAA: serum amyloid A; Th1: T helper 1
cytokine; COPD: chronic obstructive pulmonary disease.
it conserves the nutrients either as glycogen for short-term
storage or as lipids for longer storage duration, which may
result in a consequent state of obesity. The mechanisms
underlying these biological changes are beyond the scope of
this paper and the readers are directed to some excellent work
elsewhere [20, 21].
Human obesity is one of the oldest reported health disor-
ders and can be traced as early as 25,000 years; nevertheless,
it still remains relatively a rare condition for most of the
human history [22]. However, due to unparalleled socio-
demographic trends over the recent past, there has been a
drastic increase in the prevalence of obesity in most regions
of the world and particularly in developed countries [23–
25]. It was previously estimated that at least 1.1 billion
people across the globe are overweight and 312 million of
them are obese [26]. World Health Organization (WHO) has
estimated that by the end of 2030, there will be approximately
370 million people suﬀering from obesity and its associated
comorbidities [27]. In fact, the prevalence of adult obesity, as
defined by a body mass index (BMI) in excess of 30 kg/m2,
has been escalated to such a degree that a normal BMI
(18.5–24.9 kg/m2) is no longer the norm, as only a small
minority of the population will fall into this category. It
is now apparent that most countries of the world, even
those which have just recently struggled with undernutrition
(underweight), and some that continue to do so [28], are
experiencing increases in obesity prevalence. The face of
the fact is that the epidemic of obesity has now spread
throughout most of the civilized world rendering it more
appropriate to term it the “obesity pandemic.” Although
a number of potential factors have been suggested to
explain the obesity pandemic, including increased sedentary
lifestyle—particularly a decrease in occupational physical
activity [29], increased dietary caloric intake and alterations
in diet composition [24], smoking [30], and others [31], the
exact causes of the obesity pandemic are still in doubts and
continue to be debated.
3. Obesity-Induced Inflammation
Obesity in humans is associated with low-level inflammation
[32–37]. In this respect, obesity may be viewed as a form
of chronic inflammation [38]. The inflammatory response
triggered by obesity involves a number of well-known
components of the typical classical inflammatory response to
pathogens. These components include (i) systemic increases
in circulating inflammatory cytokines and adipokines and
acute phase proteins, (ii) recruitment of leukocytes to
inflamed tissues, (iii) activation of tissue leukocytes, and
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(iv) generation of reparative tissue responses (Figure 1).
However, the nature of obesity-induced inflammation is
unique in comparison to other inflammatory paradigms
of infections, autoimmune diseases, and others of the
type. Qualitatively, for example, in chronic obesity, a low-
grade activation of the innate immune system is produced
that aﬀects steady-state measures of metabolic homeosta-
sis over time. Hence obesity-associated inflammation is
characterized by a low-level but chronic inflammatory state
[39]. On the other hand, in response to pathogens or acute
injury, inflammation seems to be robust but resolves very
quickly once the threat is removed.
A great number of metabolic disorders are caused by
obesity. Among them, insulin resistance (Figure 1) has been
shown to be the most important, associated with a chronic
state of subclinical inflammation, and characterized by
increased serum concentrations of C-reactive protein [16].
In addition, interleukin (IL)-6, IL-8, monocyte chemotactic
protein (MCP)-1, and tumor necrosis factor (TNF-α) have
also been found to be increased with elevated insulin
resistance [17, 40, 41] along with factors such as serum
amyloid A, resistin, leptin, and adiponectin [42, 43]. These
may result in a large number of associated complications that
have been studied and reviewed extensively [2–11].
There are 24 diﬀerent adipokines, which have been
reported in relation to body fat and obesity [44]. The levels of
these adipokines are usually elevated in obese humans, and
circulating concentrations of each of these factors increase
with the degree of obesity. Except for IL-1, the majority
are secreted by adipocytes themselves [43, 45, 46]. Serum
amyloid-A is an adipokine secreted by adipocytes, that can
act directly on macrophages to increase its production of
inflammatory cytokines such as TNF-α, IL-1, and IL-6, and
resistin [43, 47]. Most of these adipokines are inflammatory
proteins (such as IL-8, PAI-1, MCP-1, IL-6, IL-1Ra, TNFα,
sTNF RII, and IL-18), while a few adipokines such as
CRP, haptoglobin, and amyloid A are actually acute phase
proteins primarily released by the liver in response to
mild inflammatory response associated with human obesity.
How and why these adipokines are elevated in serum in
obesity is, however, still very much unclear. Furthermore,
obesity is also associated with macrophage accumulation in
adipose tissue [48], and there is evidence that certain factors
secreted by adipocytes can act in an endocrine-like manner
to activate monocytes as well (Figure 1). For example,
resistin can induce cytokine production in macrophages,
and its production is also regulated by the inflammatory
cytokines TNF-α, IL-1, and IL-6, creating a potential positive
feedback loop [49, 50]. Leptin has the capability to exert an
endocrine eﬀect to increase cytokine production in blood
monocytes [51]. Therefore, a continuous cycle of cross-
talk between adipocytes and monocytes [52] may stimulate
and perpetuate the proinflammatory status associated with
obesity.
4. Inflammatory Signaling and Mediators of
Inflammation in Obesity
Once it was discovered that there is an increased expression
of the proinflammatory cytokine (TNFα) in adipose tissue
in obese mice, much research was focused and turned on the
key roles of inflammatory mediators in obesity [40]. It is now
well established that changes in inflammatory signaling by
adipocytes and infiltration of adipose tissue by immune cells
are the key features of obesity-induced insulin resistance and
a number of associated metabolic diseases [16, 48, 53].
It has been shown in obese mice that both adipocytes
and macrophages residing in adipose tissue secrete a number
of cytokines including TNFα, IL-6, IL-1, and migration
inhibitory factors [53]. Increased expressions of inflamma-
tory mediators (primarily cytokines but also adipokines)
have also been observed in visceral fat of obese human
individuals [53, 54]. Some of these cytokines have been
shown to cause a disruption in insulin signaling. This
disruption is attributed to a multitude of mechanisms,
including induction of the suppressors of cytokine signaling
family of proteins, which have been shown to inhibit insulin
receptor kinase activity [55, 56]. Several other in vitro and
in vivo studies suggest that TNF-α, IL-1, and IL-6 can each
directly impair insulin sensitivity by interfering with insulin-
stimulated glucose uptake in peripheral tissues [57–59].
Cytokines have also been reported to activate inflam-
matory signaling via c-Jun N-terminal kinase (JNK) and
inhibitor of kappa kinase (IKK) pathways in both immune
and neighboring nonimmune cells [60, 61]. This results
in increased inflammation and direct inhibition of insulin
action, as well as possible alterations in other metabolic
targets, that in combination contribute to overall metabolic
deterioration. The negative impact of inflammatory pathway
activation on carbohydrate metabolism has been studied
in mice [62]. Although the nature of detailed mechanisms
underlying these pathways is still in doubts, there have
been some reports of the possible causes of this impact
on carbohydrate metabolism that are attributed to deletion
of either JNK [61] or inhibition of IKK [13, 60, 63] or
even neutralization of TNF-α [40] or IL-1 [64]. These
mechanisms collectively may lead to a situation of decreased
inflammatory signaling and improved insulin responsiveness
and glucose tolerance. Immune and neighboring nonim-
mune cells have been shown to be important in the observed
improvements in glucose homeostasis [13, 15, 60, 65]. Of
particular note, manipulation of levels of these inflammatory
mediators can impact insulin resistance and other metabolic
parameters whether it is adipose cell accumulation in muscle
or lipid accumulation in liver [16]. This may be an indication
that alterations in immune signaling are triggered by excess
adiposity, which may be essential mediators of the metabolic
dysfunction observed in obesity.
Macrophage infiltration has also been observed in skele-
tal muscle, suggesting that local inflammatory signaling
could also directly influence muscle insulin resistance [66].
It is important to note that in many experimental systems,
muscle eﬀects appear to emerge secondary to alterations in
other organs, including adipose tissue and liver [67]. How-
ever, muscle-specific expression of the anti-inflammatory
cytokine IL-10 has been shown to greatly improve muscle
insulin sensitivity, consequently yielding reduced inflam-
mation in this tissue despite normal development of obe-
sity when fed a high-fat diet [68]. In addition, increased
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inflammatory signaling in the brain has also been observed
in response to overnutrition, or in the context of obesity,
resulting in improper regulation of energy uptake and energy
expenditure by peripheral tissues [69]. Thus, it appears
that increased inflammation is a systemic feature associated
with surplus energy intake. Therefore interventional or
therapeutic solutions for reducing inflammatory signaling
induced by metabolic stress would, therefore, be necessarily
expected to improve on systemic energy homeostasis at
multiple tissue and organ or system levels.
5. Metabolically Healthy and Unhealthy
Phenotypes of Obesity
5.1. Metabolically Healthy Obesity. Not all obese individuals
exhibit increased risk of inflammation and not all normal-
weight individuals are metabolically healthy or free from
CVD [70]. Two distinct subtypes of obesity have been
proposed, referred to in diﬀerent ways by various authors.
One type is “metabolically healthy” and the other is
“metabolically unhealthy” obese (MHO and MUHO, resp.).
It is interesting to note that approximately 20–30% of the
adult obese population remains at the level of relatively
“metabolically healthy” obesity (MHO) [18, 19, 70] as
compared to those with “metabolically unhealthy” obesity
(Figure 2). Individuals in the first subtype have also been
termed “metabolically normal obese” [71], “metabolically
healthy but obese” [70], “obese metabolically normal” [72]
or described as having metabolically benign obesity [73]
or uncomplicated obesity [74]. MHO individuals exhibit
increased levels of body mass index (BMI) and body fat (BF)
but no other metabolic complications [72]. Significantly,
both subtypes associate with diﬀerent inflammatory profiles.
MUHO exhibit increased levels of inflammation compared
to other normal-weight individuals [75], while MHO exhibit
reduced levels of inflammation compared to other obese
individuals [76]. MHO individuals may display an absence
of impaired glucose tolerance, dyslipidemia, hyperuricemia,
and hypertension [19]. In addition, their metabolic and
CVD risk profiles are relatively mild [77], with high levels
of insulin sensitivity [71], absence of hypertension [78],
normal lipid, inflammation, and hormonal profiles [73], and
importantly a favorable immune profile [79]. It has been
suggested that the unique metabolically healthy subgroup of
obese individuals appear to be protected or more resistant
to the development of comorbidities associated with obesity
[70–72, 80].
Despite the knowledge of the MHO phenotype for
substantially longer time now, there still currently exist no
established criteria for the definition of MHO individu-
als [80]. Some have used arbitrary cut-points of insulin
sensitivity [19], cardiometabolic risk factor clustering [73],
or the complete absence of any metabolic aberration [74]
to delineate MHO from MUHO individuals. Furthermore,
no convincing answers on how the mechanism is in place
which provides protection against a number of diseases in
MHO individuals. Several hypotheses have been proposed
in an attempt to explain the role of the adipose tissue
in the metabolic dysfunction associated with obesity in
order to better understand the diﬀerence between the two
distinct groups (Figure 2). Thus, the altered pattern of
adipokine secretion by the obese adipose tissue [81, 82],
the inflammatory state associated with obesity [83], or the
inability of the adipose tissue to expand its mass in response
to increased energy intake [84] have all been signaled as
possible culprits. However, all these diﬀerent hypotheses
are not mutually exclusive. As a plausible mechanism for
the normal cardiometabolic profile, it has been reported
that for the same BMI, MHO subjects tend to have a
lower waist circumference [19], and specifically less VAT
accumulation [71] in contrast to MUHO individuals, there-
fore, closely resembling the metabolically benign gynoid
obesity phenotype. Some recent studies have shown that
increased visceral/abdominal fat (characteristics of MUHO)
is positively associated with metabolic disease [85, 86], inde-
pendent of overall adiposity [87, 88]. Similarly, high thigh
intermuscular fat is associated with poorer glucose tolerance.
On the other hand, subcutaneous thigh fat (characteristic of
MHO) is associated withmore favorable levels of glucose and
lipids [89, 90]. Another explanation for the more favorable
metabolic profile of some obese people may be related to
inflammatory status [91].
Another critical unanswered question is why and how
MHO individuals may diﬀer from MUHO regarding the
inflammatory mediators in obesity. Inflammatory markers,
such as IL-6, TNF-α and other cytokines and adipokines such
as resistin and adiponectin are associated with metabolic
alterations [92, 93]. These adipocytokines are closely linked
to abdominal obesity, particularly to visceral adipose tissues,
while some evidence suggests that thigh subcutaneous fat
is related to more favorable inflammatory profiles [94–96].
Overall, the unique protective mechanism in these individu-
als is attributable in part to a reduced inflammatory profile
[77], and uncoupling of inflammatory signal transduction
from obesity-driven inflammatory response [97, 98].
Theoretically, MHO and MUHO may represent distinct
subtypes of obesity that were predetermined genetically to
confer diﬀering metabolic and cardiovascular risks. Another
theoretical possibility is that MHO and MUHO represent
transitions phases from nonobesity in the development and
natural history of obesity, with MHO individual ultimately
turning into MUHO. It is tempting to think over the
possibility of the other way round, that is, the possibility of
converting MUHO into MHO. Whether MHO is sustained
or not for substantially a longer period may depend upon a
number of factors, including the levels of cytokines and/or
adipokines. A major challenge is to understand both the
initiating signals and downstream mechanisms involved in
the establishment of inflammation that occurs during these
transitions from relatively healthy form of obesity into
unhealthy one. Further studies are needed to investigate
the diﬀerences in concentrations of these inflammatory
factors and to establish whether it is an imbalance in the
concentrations of these cytokines that causes this transition
or whether the transition to MUHO occurs first due to
various other factors and then brings about changes in the
levels of these cytokines (which came first, the chicken or
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• Metabolic complication ++
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Figure 2: Diﬀerences between metabolically healthy and unhealthy obesity and similarities with aging. The hallmarks of metabolically
healthy obesity are depicted and associate poorly with comorbidities while metabolically unhealthy obesity shares similarities with the aging
process and are both associated with increased prevalence to pathologies and chronic conditions. BMI: bodymass index; CVD: cardiovascular
diseases.
the egg?). The answer to this question may have paramount
clinical and public health implications. Once the temporal
relationship is established, the course of obesity can be
stopped or delayed at some stage during its natural history
before it becomes “metabolically unhealthy.”
One possible way to investigate the mode of this tran-
sition is to study obesity over enough time to observe the
impact of its related chronic inflammation. Thus, after the
5th decade may be the best time to study such transitions, for
a number of reasons. First, this is the age where an individual
starts entering into old age, particularly in the developing
countries [99]. Second, most of the changes in hormonal
output and functions [100], life-style behaviors [101],
diet and nutrition, body composition [99, 102, 103], and
immunological alterations [104, 105], and overall physical,
physiological, and immunological parameters [106, 107] are
likely to emerge significantly diﬀerently in the elderly with an
overall impact on obesity and the inflammatory mediators.
Third, obesity is more prevalent in older age. Finally, part of
the comorbidity associated with obesity is common to aging
(Figure 2) and may suggest similar mechanisms. In relation
to obesity, the transition between MHO and MUHO is likely
to occur from adulthood-to-early old age and hence it may
be wise to focus on obesity and its related issues at this age.
In the last sections of this paper, an overview of
metabolically healthy and unhealthy obesity in the context of
aging is presented followed by a description of obesity- and
age-associated inflammation.
5.2. Metabolically Healthy Obesity in Old Age. A clear dis-
tinction between MHO and MUHO is even of great clinical
implication in the aged subjects as ageing populations face
the challenges of both rising numbers of the elderly and
increasing obesity prevalence. In addition, elderly subjects
may present with diﬀerences in the etiology, pathogenesis
and prevalence of obesity and its comorbidities and related
inflammatory patterns and implications.
It is important to note that the prevalence of overweight
and obesity is increasing among older age groups in devel-
oped countries [108]. The prevalence of obesity increases
from 15 to 20% at puberty to 40% in 60–69 years old
individuals [109, 110], which is also a rational for studying
obesity in this age group in particular. The problem of
obesity in the elderly thus has great relevance and requires
more research and clinical attention.
Research studies so far have not considered in greater
depth the phenotypic heterogeneity of obesity such as the
metabolically healthy and unhealthy subtypes, particularly
in the aged populations. In virtually all studies, measures of
adiposity were investigated alongside metabolic risk factors
and individual components of the metabolic syndrome
as independent risk factors predicting health outcomes.
The health risks of overweight-obese individuals without
metabolic risk factors and those with metabolic risk factors
have been investigated, to the best of our knowledge, in one
study so far [111]. This longitudinal study assessed risk for
diabetes or cardiovascular disease (CVD) stratified by body
mass index (BMI) and the presence or absence of metabolic
syndrome (MetS) or insulin resistance (IR). It found that
metabolic risk factor clustering or IR appeared to confer
much of the risk for diabetes or CVD commonly associated
with elevated BMI. Of note, among people older than 70
years, there is decline in obesity prevalence probably due
to selective mortality of people in middle ages, such that
relatively fewer obese people survive into older ages. Aging
is also associated with emergence of frailty and sarcopenia
which are partly defined by weight loss, especially fat-
free muscle. Thus, very old individuals may convert from
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obesity defined by increased BMI to obesity due to reduced
muscle/fat ratio but with a normal BMI. In connection
to that, the normal-weight obese (NWO) syndrome in the
elderly subjects of normal body weight and BMI has been
identified (Figure 2). Interestingly, the fat mass in these
subjects was 30% of their total body weight and these
subjects had a likelihood of increased risk of developing
obesity-related diseases [112]. The data suggests that in
the elderly obesity should be redefined as the amount of
excess fat storage associated with elevated health risk. The
relationship between overweight/obesity and total mortality
in the elderly is controversial [113]. The expected increase on
mortality associated with increasing BMI is not observed in
many older population studies, and a number of studies, in
fact, observed a U-shaped curve describing the relationship
between BMI and mortality in old age [114]. Higher BMI
values were associated with a smaller relative mortality risk
in elderly persons compared with young and middle-aged
populations [115]. These data suggest that use of BMI
alone as the sole indices of excess adiposity in studies of
older populations is a contributing factor for discrepant
findings. On the other hand, studies using indices of amount
and distribution of fat tend to consistently show a greater
association with specific and total mortality in the elderly
than BMI alone. Larger waist circumference or waist-to-
hip ratio (relatively stronger indicators for adiposity) has
been shown significantly associated with mortality in older
subjects, whilst BMI alone was not. Thus, central adiposity
and relative loss of fat-free mass may bemore important than
BMI in determining the health risk associated with obesity
in older ages. The interpretation of the relationship between
adiposity and mortality in the elderly is complicated by the
diﬃculty in accounting for selection and confounding factors
(such as survival bias, smoking, and physical inactivity), but
is probably also inherently complex.
Numerous studies have shown that overweight/obesity is
associated with a host of known nonfatal health outcomes,
mostly in the aged populations [116–122]. Hypothetically,
MUHO might be responsible for much of the association
with metabolic syndrome, diabetes, cardiovascular disease,
and other obesity-related metabolic complications includ-
ing depression and dementia; on the other hand, MHO
might still be associated with similar risk of other related
complications such as physical limitations and disability,
osteoarthritis, and obstructive sleep apnea. As with total
mortality, a J-shape relation between BMI and disability in
older persons has been reported [118] with observed greater
disability for both low and high values of BMI in both
sexes. The relationships with variousmorbidity outcomes are
particularly stronger with indices of central adiposity than
BMI, and some indeed showed associations independently
of BMI. Taking another case in point, although some studies
showed a significant negative relationship between high BMI
and depressive symptoms (Jolly Fat hypothesis) [123, 124]
other studies showed that increased waist circumference was
either not associated or positively associated with depressive
symptoms [125, 126].
6. Aging and Inflammation
In the previous sections, obesity and its diﬀerent phenotypic
forms were reviewed with emphasis of possible diﬀerences
due to natural aging. The consequences related to MHO and
MUHO are likely to be greatly aﬀected by aging as a variety
of disorders and infections are unique to the elderly, which
may additionally exacerbate the eﬀects of obesity. Thus, aging
seems to present with a great variety of patterns and unique
sets of obesity and age-related infections and diseases. It
is, therefore, very tempting and urging to study obesity,
inflammation, and the related comorbidities in the context
of aging.
In general, inflammation is a very tightly regulated
process that ensures recruitment of competent and expe-
rienced cells, clearance of pathogen with minimal tissue
damage and sequels. The duration, intensity and variety
of its components will determine the impact of inflam-
mation on health including the cardiovascular, bone/joint,
respiratory and immune systems. A lack of balance in this
equilibrium may lead to significant consequences locally
(tissue site) or in a systemic manner. Inflammation is the
most necessary step for recovery and most cells produce
cytokines/chemokines/adipokines and soluble mediators of
inflammation. Not only immune cells but also endothelial
cells, fibroblasts, and keratinocytes among other cell types
are able to produce these mediators and are partners and
players of the immune responses, fully involved in the
inflammatory process. One example is the atherosclerotic
plaques that develop over years. There is no doubt in the
scientific community regarding the involvement of mono-
cytes/macrophages in the formation of these plaques. The
increase in oxidized low-density-lipoproteins (oxLDL) and
its associated secretion of proinflammatory molecules from
the endothelium is responsible for the initial recruitment
of immune cells (Figure 3). The molecular events leading
to LDL oxidation and subsequent eﬀects are extensively
reviewed by Leonarduzzi et al. [127]. Briefly, the mono-
cytes diﬀerentiate into macrophages, which possess a high
propensity to uptake oxLDL. The uncontrolled accumulation
of the oxLDL initiates the formation of lipid droplets
within the monocytes/macrophages, ultimately leading to
the formation of foam cells. These foam cells in turn release
proinflammatory mediators that sustain this process. The
accumulation of foam cells leads to the formation of a
physical barrier in the vessels characterizing atherosclerosis.
This pathology is a process that requires years or decades to
be observed clinically. For this reason, many consequences of
uncontrolled inflammation are seen later in life, that is, in the
elderly population. Recent animal models (zebra fish) allow
to now study and modulate the eﬀect of oxLDL in a shorter
period of time [128], which should enable to improve our
understanding of relationship between inflammation and
obesity-related diseases.
Cardiovascular diseases (CVD), including heart and
vascular disease and atherosclerosis, are highly prevalent,
particularly in the old age. Inflammation induced by obesity
accelerates atherosclerosis. Adipose tissue and adipocytes
produce leptin and large numbers of a variety of other


























Figure 3: Conversion of naı¨ve LDL to oxidized LDL and formation of foam cells from monocytes: implication of aging and obesity in
sustaining/worsening inflammation. A typical example of how chronic condition can participate in the development of diseases. In this case,
atherosclerotic plaque formation is increased by parallel proinflammatory signals derived from obesity and/or inflammaging. LDL: low-
density lipoprotein; ROS: reactive oxygen species; CMV: cytomegalovirus; RANTES: regulated and normal T cell expressed and secreted.
hormones, peptides, and other molecules that aﬀect car-
diovascular function. The production of these substances is
supposed to be through distinct endocrine, autocrine and
paracrine mechanisms and believed to lead to cytokine-
mediated inflammatory changes in the liver and systemic
inflammation and atherosclerosis [129]. CVD and the related
heart diseases are recognized as chronic inflammatory con-
ditions of the blood vessels that result from the excessive
transendothelial passage (transcytosis) of cholesterol rich
atherogenic lipoproteins (VLDL, IDL, and LDL) from the
plasma into the intima. Once there, these lipoproteins are
likely to be retained in the subendothelial spaces leading to
infiltration of macrophages and T cells into these spaces and
ultimately interact not only with each other but also with
the cells of the arterial wall [130–132], forming foam cells
(FC) in the vicinity [133], which is considered as the first
step of plaque formation (Figure 3). FC are generated from
altered and/or oxidized LDL, termed as modified LDL. The
rate and intensity of FC formation depends upon the relative
size and shape of LDL [134] as LDL comprises a group
of very heterogeneous particles, which comprise multiple
distinct subclasses that diﬀer in size, density, physicochemical
composition, metabolic and oxidative behavior, as well as
atherogenicity [135]. Increasing evidence suggests that size
and density of LDL have a direct influence on cardiovascular
risk [136]. There is also evidence suggestive of the coexistence
of proatherogenic LDL subclasses and elevated inflammation
[137]. For instance, elevated levels of IL-18 are associated
with reduced LDL size, independently of other inflammatory
and metabolic risk factors [138]. There is a close relationship
between atherogenic small, dense LDL and inflammation
[139] and a reduction in the concentrations of these LDL has
been shown to lead to a strong reduction in CVD-associated
morbidity and mortality rate [140–142].
Based on the observations of greater than expected
reduction in CVD events in the JUPITER study (Justification
for the Use of Statins in Primary Prevention: An Intervention
Trial Evaluating Rosuvastatin) [143], it has been suggested
that other factors besides LDL-cholesterol may also be
involved in the reduction of CVD event. Therefore the
modulation of these factors, particularly of inflammation
and atherogenic lipoproteins, represents a main target of
CVD prevention [144]. In addition, there is overwhelming
evidence supporting the pathogenetic role of fibrinogen and
CRP in atherosclerosis [145] and their predictive capability
for future cerebro- and cardiovascular events in patients with
subclinical and clinical atherosclerosis [146–148].
Obesity and type 2 diabetes (T2D) are probably inter-
twined. Unfortunately, however, no direct study has ever
provided the evidence that obesity can cause diabetes.
Interestingly, reports published by Solinas et al. [15] indicate
that inflammation could be the key factor causing obesity-
induced type 2 diabetes. The group has indicated that obesity
without inflammation is not prominently associated with
insulin resistance and/or diabetes. In addition, gestational
diabetes (GDM) is very common and high prevalence rates
have been reported from both developed and developing
countries [149–152]. Women with previous gestational
diabetes (pGDM) are characterized by chronic subclinical
inflammation which is associated with insulin resistance
and abnormality in glucose metabolism. Approximately 30%
of these women have metabolic syndrome and many of
them will develop T2DM within 5 years of diagnosis. The
conversion rates from GDM to T2DM range from 2.6% to
70% over a period of 6 weeks to 28 years postpartum [153].
As described in the previous section, obesity is not
restricted to younger populations. However, the intensity
of obesity-related inflammation may not be the same
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over age. Also, obesity-related or unrelated inflammation
may not be similarly handled in young versus elderly
individuals. This raises the importance of understanding
the unbalance in inflammation during aging. Two types
of unwanted inflammation must be considered in aging
(i) acute inflammation resulting from bad management
of the inflammatory process, which in turn results from
immune responses, and (ii) chronic inflammation resulting
from persistent condition(s) in the elderly including age-
specific infections such as cytomegalovirus CMV. This later
is often referred to as low-grade inflammation or even
“inflammaging” as coined by Franceschi et al. [154], who
identified a variety of these proinflammatory mediators in
aging [155], namely, RANTES, MIP-1α, IL-8, MCP-1, IL-
6, and TNF-α amongst others. Individually these mediators
are involved in the development of many subclinical and
clinically assessable events such as atherosclerosis, dementia,
and diabetes (Figure 3). Not only is the presence of these
markers in higher quantity linked to comorbidities but also
tomortality [155]. The unbalance between IL-6/TNF-α levels
and IGF-I levels in the elderly directly accounts for the loss
of fat-free mass suggesting that obesity and sarcopenia are
highly inflammation dependent [156]. An important set of
markers is IL-6, TNF-α, and CRP. This triad is involved in
much comorbidity and has shown significant correlations
with mortality [157]. The increased levels of such inflam-
matory mediators are not observed in all elderly individuals.
Many mechanisms influence how inflammation is resolved
and many events will induce such inflammation. Genetics
lifestyle and immunological history are probably the most
important players in the inter-individual diﬀerences [158].
Immunological history refers to the collection of events that
lead to an immune response. This response may result in
clearance of infection (acute response) or may simply resolve
primary infection without clearing the pathogen. This later,
chronic/persistent infection is a major issue for the immune
system as it requires life-long immunosurveillance and
dedicated resources. Pathogens requiring life-long control
can be viruses (HIV, Cytomegalovirus), bacteria (H. pylori,
M. tuberculosis), or parasites (P. falciparum, T. gondii). HIV
has been shown to deeply impact on body composition such
as increased visceral adipose tissue even with therapies. Such
changes were also associated to increased susceptibility to
atherosclerosis and associated complications suggesting that
inflammation may be a corner stone in these processes [159].
Helicobacter pylori is now easily eradicated following
its identification, however, there is evidence showing that
even after resolution of infection there is no reduction
in the incidence of gastric cancers suggesting that the
inflammation initiated has long-lasting eﬀects suggesting
that immunological history in this case have irreversible
eﬀects [160]. While the infection with HIV, parasites, and
even H. pylori may be reduced greatly in the next decades
and already low in developed countries, a majority of indi-
viduals encounter CMV during their life. The seroconversion
ranges between 0.5 and 1.5% per year [161] but may be
very high in younger populations, especially in developing
countries. Thus, such a persistent infection may impact on
individuals’ health for decades. One of the most important
studies on the relationship between CMV seropositivity and
mortality was performed recently in a US-based platform
[162]. Individuals aged 25 and above from the NHANES
III (started in 1988) were followed-up for mortality and
adjustment for multiple confounders revealed that CMV
seropositivity was statistically significantly associated with
all-cause mortality. Individuals with high CRP levels showed
a 30% higher risk for all-cause and cardiovascular diseases-
mortality compared to those with low CRP levels. That
study however did not investigate the putative synergy
of obesity and CMV seropositivity on all-cause mortal-
ity.
7. Conclusion
Obesity in humans is a unique form of low-grade inflamma-
tion. In chronic obesity, a low-grade activation of the innate
immune system is provoked aﬀecting metabolic homeosta-
sis steadily. In contrast to the inflammatory response to
pathogens or acute injury which is robust but resolves
very quickly once the threat is removed, inflammation in
obesity seems to sustain for relatively longer period of time.
Inflammatory state of obesity is characterized by insulin
resistance, increased serum concentrations of C-reactive
protein, IL-6, IL-8, TNF-α, and so forth. Obesity-induced
insulin resistance also causes changes in inflammatory
signaling by adipocytes and infiltration of adipose tissue by
immune cells. Alterations in immune signaling are triggered
by excess adiposity, which may be essential mediators of the
metabolic dysfunction observed in obesity. However, not all
obese individuals exhibit increased risk of inflammation and
not all normal-weight individuals are metabolically healthy.
A critical unanswered question is why and how the diﬀerence
exists between metabolically healthy and unhealthy obese
individuals regarding the obesity-associated inflammatory
mediators. The answers to this question becomes even more
important in the context of elderly, who present with diverse
but more complex dimensions of body weight, patterns of
body fat distribution, and obesity. This is why now, for
example, there is great disagreement among the researchers
whether to use the conventional BMI as an indicator of health
outcomes or not as BMI is considered not sensitive enough
to discriminate between lean body mass and body fat, partic-
ularly in elderly. Unfortunately, much of the previous work
on the elderly focused on obesity assessed by BMI without
considering the overall metabolic profile, which often yield
controversial conclusions and misleading interpretations
about obesity and its related comorbidities. Nevertheless, the
association between obesity, morbidity, functional disability,
and evenmortality has been well established. It is noteworthy
that the intensity of obesity-related inflammationmay not be
the same over age and unlike young, elderly may be victims
of chronic inflammation beside acute inflammation, which
results from persistent condition(s) in the elderly over the
course of life-span including specific infections, CMV, for
example. This state of chronic inflammation is often referred
to as low-grade inflammation or even “inflammaging,”
characterized by a variety of proinflammatory mediators
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with aging, namely, RANTES, MIP-1α, IL-8, MCP-1, IL-
6, and TNF-α amongst others. As depicted in the paper,
this resembles to some extent to the obesity-related inflam-
mation. Individually, these mediators are involved in the
development of many subclinical and clinically assessable
events such as atherosclerosis, dementia, and diabetes in
old age, which linked to a number of other comorbidities
and the overall mortality. While the prevalence of most of
current infections is decreasing, elderly individuals are more
susceptible to infections, respond poorly to vaccination. The
role of inflammation in immune erosion is to be considered
seriously, especially when other chronic conditions such as
obesity are present.
References
[1] P. Zimmet, K. G. M. M. Alberti, and J. Shaw, “Global and
societal implications of the diabetes epidemic,” Nature, vol.
414, no. 6865, pp. 782–787, 2001.
[2] A. C. Evans, G. I. Papachristou, and D. C. Whitcomb, “Obe-
sity and the risk of severe acute pancreatitis,” Minerva
Gastroenterologica e Dietologica, vol. 56, no. 2, pp. 169–179,
2010.
[3] H. Tilg, “The role of cytokines in non-alcoholic fatty liver
disease,” Digestive Diseases, vol. 28, no. 1, pp. 179–185, 2010.
[4] C. X. Andersson, B. Gustafson, A. Hammarstedt, S. Hedjaz-
ifar, and U. Smith, “Inflamed adipose tissue, insulin resis-
tance and vascular injury,” Diabetes/Metabolism Research and
Reviews, vol. 24, no. 8, pp. 595–603, 2008.
[5] F. Gomes, D. F. Telo, H. P. Souza, J. C. Nicolau, A. Halpern,
and C. V. Serrano, “Obesity and coronary artery disease: role
of vascular inflammation,” Arquivos Brasileiros de Cardiolo-
gia, vol. 94, no. 2, pp. 255–279, 2010.
[6] R. Tkacova, “Systemic inflammation in chronic obstructive
pulmonary disease: may adipose tissue play a role? Review
of the literature and future perspectives,” Mediators of
Inflammation, vol. 2010, Article ID 585989, 11 pages, 2010.
[7] A. Denes, P. Thornton, N. J. Rothwell, and S. M. Allan,
“Inflammation and brain injury: acute cerebral ischaemia,
peripheral and central inflammation,” Brain, Behavior, and
Immunity, vol. 24, no. 5, pp. 708–723, 2010.
[8] M. K. O¨hman, A. P. Wright, K. J. Wickenheiser, W. Luo, and
D. T. Eitzman, “Visceral adipose tissue and atherosclerosis,”
Current Vascular Pharmacology, vol. 7, no. 2, pp. 169–179,
2009.
[9] S. D. Hursting, L. M. Lashinger, K. W. Wheatley et al.,
“Reducing the weight of cancer: mechanistic targets for
breaking the obesity-carcinogenesis link,” Best Practice and
Research, vol. 22, no. 4, pp. 659–669, 2008.
[10] D. L. Roberts, C. Dive, and A. G. Renehan, “Biological mech-
anisms linking obesity and cancer risk: new perspectives,”
Annual Review of Medicine, vol. 61, pp. 301–316, 2010.
[11] K. Y. Wolin, K. Carson, and G. A. Colditz, “Obesity and
cancer,” Oncologist, vol. 15, no. 6, pp. 556–565, 2010.
[12] J. P. Bastard, M. Maachi, C. Lagathu et al., “Recent advances
in the relationship between obesity, inflammation, and
insulin resistance,” European Cytokine Network, vol. 17, no.
1, pp. 4–12, 2006.
[13] M. C. Arkan, A. L. Hevener, F. R. Greten et al., “IKK-β links
inflammation to obesity-induced insulin resistance,” Nature
Medicine, vol. 11, no. 2, pp. 191–198, 2005.
[14] S. P. Weisberg, D. Hunter, R. Huber et al., “CCR2 modulates
inflammatory and metabolic eﬀects of high-fat feeding,”
Journal of Clinical Investigation, vol. 116, no. 1, pp. 115–124,
2006.
[15] G. Solinas, C. Vilcu, J. G. Neels et al., “JNK1 in hematopoi-
etically derived cells contributes to diet-induced inflamma-
tion and insulin resistance without aﬀecting obesity,” Cell
Metabolism, vol. 6, no. 5, pp. 386–397, 2007.
[16] S. E. Shoelson, J. Lee, and A. B. Goldfine, “Inflammation and
insulin resistance,” Journal of Clinical Investigation, vol. 116,
no. 7, pp. 1793–1801, 2006.
[17] S. E. Kahn, B. Zinman, S. M. Haﬀner et al., “Obesity is a
major determinant of the association of C-reactive protein
levels and the metabolic syndrome in type 2 diabetes,”
Diabetes, vol. 55, no. 8, pp. 2357–2364, 2006.
[18] N. B. Ruderman, S. H. Schneider, and P. Berchtold, “The
“metabolically-obese” normal-weight individual,” American
Journal of Clinical Nutrition, vol. 34, no. 8, pp. 1617–1621,
1981.
[19] R. P. Wildman, P. Muntner, K. Reynolds et al., “The
obese without cardiometabolic risk factor clustering and the
normal weight with cardiometabolic risk factor clustering:
prevalence and correlates of 2 phenotypes among the US
population (NHANES 1999–2004),” Archives of Internal
Medicine, vol. 168, no. 15, pp. 1617–1624, 2008.
[20] S. B. Racette, S. S. Deusinger, and R. H. Deusinger, “Obesity:
overview of prevalence, etiology, and treatment,” Physical
Therapy, vol. 83, no. 3, pp. 276–288, 2003.
[21] W. D. McArdle, F. I. Katch, and V. L. Katch, Exercise Physiol-
ogy: Energy, Nutrition, and Human, Lippincott Williams and
Wilkins, Philadelphia, Pa, USA, 2001.
[22] L. A. Helmchen and R. M. Henderson, “Changes in the
distribution of body mass index of white US men, 1890–
2000,” Annals of Human Biology, vol. 31, no. 2, pp. 174–181,
2004.
[23] P. T. Katzmarzyk, “The Canadian obesity epidemic, 1985–
1998,” Canadian Medical Association Journal, vol. 166, no. 8,
pp. 1039–1040, 2002.
[24] K. Silventoinen, S. Sans, H. Tolonen et al., “Trends in
obesity and energy supply in the WHO MONICA Project,”
International Journal of Obesity, vol. 28, no. 5, pp. 710–718,
2004.
[25] K. M. Flegal, M. D. Carroll, R. J. Kuczmarski, and C. L.
Johnson, “Overweight and obesity in the United States:
prevalence and trends, 1960–1994,” International Journal of
Obesity, vol. 22, no. 1, pp. 39–47, 1998.
[26] P. T. James, N. Rigby, and R. Leach, “The obesity epidemic,
metabolic syndrome and future prevention strategies,” Euro-
pean Journal of Cardiovascular Prevention and Rehabilitation,
vol. 11, no. 1, pp. 3–8, 2004.
[27] S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global
prevalence of diabetes: estimates for the year 2000 and
projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–
1053, 2004.
[28] A. M. Prentice, “The emerging epidemic of obesity in
developing countries,” International Journal of Epidemiology,
vol. 35, no. 1, pp. 93–99, 2006.
[29] J. O. Hill and E. L. Melanson, “Overview of the determinants
of overweight and obesity: current evidence and research
issues,” Medicine and Science in Sports and Exercise, vol. 31,
no. 11, pp. S515–S521, 1999.
[30] K.M. Flegal, R. P. Troiano, E. R. Pamuk, R. J. Kuczmarski, and
S. M. Campbell, “The influence of smoking cessation on the
10 Mediators of Inflammation
prevalence of overweight in the United States,” New England
Journal of Medicine, vol. 333, no. 18, pp. 1165–1170, 1995.
[31] P. F. Baillie-Hamilton, “Chemical toxins: a hypothesis to
explain the global obesity epidemic,” Journal of Alternative
and Complementary Medicine, vol. 8, no. 2, pp. 185–192,
2002.
[32] K. Clement and D. Langin, “Regulation of inflammation-
related genes in human adipose tissue,” Journal of Internal
Medicine, vol. 262, no. 4, pp. 422–430, 2007.
[33] A. W. Ferrante Jr., “Obesity-induced inflammation: a
metabolic dialogue in the language of inflammation,” Journal
of Internal Medicine, vol. 262, no. 4, pp. 408–414, 2007.
[34] S. Engeli and A. M. Sharma, “Role of adipose tissue
for cardiovascular-renal regulation in health and disease,”
Hormone and Metabolic Research, vol. 32, no. 11-12, pp. 485–
499, 2000.
[35] K. M. Pou, J. M. Massaro, U. Hoﬀmann et al., “Visceral and
subcutaneous adipose tissue volumes are cross-sectionally
related to markers of inflammation and oxidative stress. The
Framingham Heart Study,” Circulation, vol. 116, no. 11, pp.
1234–1241, 2007.
[36] P. Trayhurn and I. S. Wood, “Adipokines: inflammation and
the pleiotropic role of white adipose tissue,” British Journal of
Nutrition, vol. 92, no. 3, pp. 347–355, 2004.
[37] K. E. Wellen and G. S. Hotamisligil, “Inflammation, stress,
and diabetes,” Journal of Clinical Investigation, vol. 115, no. 5,
pp. 1111–1119, 2005.
[38] U. N. Das, “Is obesity an inflammatory condition?” Nutri-
tion, vol. 17, no. 11-12, pp. 953–966, 2001.
[39] G. S. Hotamisligil, “Inflammation and metabolic disorders,”
Nature, vol. 444, no. 7121, pp. 860–867, 2006.
[40] G. S. Hotamisligil, N. S. Shargill, and B. M. Spiegelman,
“Adipose expression of tumor necrosis factor-α: direct role in
obesity-linked insulin resistance,” Science, vol. 259, no. 5091,
pp. 87–91, 1993.
[41] C. S. Kim, H. S. Park, T. Kawada et al., “Circulating levels of
MCP-1 and IL-8 are elevated in human obese subjects and
associated with obesity-related parameters,” International
Journal of Obesity, vol. 30, no. 9, pp. 1347–1355, 2006.
[42] P. Arner, “Insulin resistance in type 2 diabetes—role of the
adipokines,” Current Molecular Medicine, vol. 5, no. 3, pp.
333–339, 2005.
[43] H. Tilg and A. R. Moschen, “Adipocytokines: mediators
linking adipose tissue, inflammation and immunity,” Nature
Reviews Immunology, vol. 6, no. 10, pp. 772–783, 2006.
[44] J. N. Fain, “Release of inflammatory mediators by human
adipose tissue is enhanced in obesity and primarily by the
nonfat cells: a review,” Mediators of Inflammation, vol. 2010,
Article ID 513948, 20 pages, 2010.
[45] P. A. Kern, M. Saghizadeh, J. M. Ong, R. J. Bosch, R. Deem,
and R. B. Simsolo, “The expression of tumor necrosis factor
in human adipose tissue. Regulation by obesity, weight loss,
and relationship to lipoprotein lipase,” Journal of Clinical
Investigation, vol. 95, no. 5, pp. 2111–2119, 1995.
[46] M. Good, F. M. Newell, L. M. Haupt, J. P. Whitehead, L. J.
Hutley, and J. B. Prins, “TNF and TNF receptor expression
and insulin sensitivity in human omental and subcutaneous
adipose tissue—influence of BMI and adipose distribution,”
Diabetes and Vascular Disease Research, vol. 3, no. 1, pp. 26–
33, 2006.
[47] R. Z. Yang, M. J. Lee, H. Hu et al., “Acute-phase serum amy-
loid A: an inflammatory adipokine and potential link
between obesity and its metabolic complications,” PLoS
Medicine, vol. 3, no. 6, article e287, 2006.
[48] S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R.
L. Leibel, and A. W. Ferrante Jr., “Obesity is associated
with macrophage accumulation in adipose tissue,” Journal of
Clinical Investigation, vol. 112, no. 12, pp. 1796–1808, 2003.
[49] M. Lehrke, M. P. Reilly, S. C. Millington, N. Iqbal, D. J.
Rader, and M. A. Lazar, “An inflammatory cascade leading to
hyperresistinemia in humans,” PLoS Medicine, vol. 1, article
45, 2004.
[50] N. Silswal, A. K. Singh, B. Aruna, S. Mukhopadhyay,
S. Ghosh, and N. Z. Ehtesham, “Human resistin stimu-
lates the pro-inflammatory cytokines TNF-α and IL-12 in
macrophages by NF-κB-dependent pathway,” Biochemical
and Biophysical Research Communications, vol. 334, no. 4, pp.
1092–1101, 2005.
[51] V. Sa´nchez-Margalet, C. Martı´n-Romero, J. Santos-Alvarez,
R. Goberna, S. Najib, and C. Gonzalez-Yanes, “Role of leptin
as an immunomodulator of blood mononuclear cells: mech-
anisms of action,” Clinical and Experimental Immunology,
vol. 133, no. 1, pp. 11–19, 2003.
[52] T. Suganami, J. Nishida, and Y. Ogawa, “A paracrine loop
between adipocytes and macrophages aggravates inflamma-
tory changes: role of free fatty acids and tumor necrosis factor
α,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25,
no. 10, pp. 2062–2068, 2005.
[53] J. M. Olefsky and C. K. Glass, “Macrophages, inflammation,
and insulin resistance,” Annual Review of Physiology, vol. 72,
pp. 219–246, 2009.
[54] G. S. Hotamisligil, P. Arner, J. F. Caro, R. L. Atkinson,
and B. M. Spiegelman, “Increased adipose tissue expression
of tumor necrosis factor-α in human obesity and insulin
resistance,” Journal of Clinical Investigation, vol. 95, no. 5, pp.
2409–2415, 1995.
[55] J. K. Howard and J. S. Flier, “Attenuation of leptin and insulin
signaling by SOCS proteins,” Trends in Endocrinology and
Metabolism, vol. 17, no. 9, pp. 365–371, 2006.
[56] P. Lebrun and E. Van Obberghen, “SOCS proteins causing
trouble in insulin action,” Acta Physiologica, vol. 192, no. 1,
pp. 29–36, 2008.
[57] G. S. Hotamisligil, P. Peraldi, A. Budavari, R. Ellis, M. F.
White, and B. M. Spiegelman, “IRS-1-mediated inhibition
of insulin receptor tyrosine kinase activity in TNF-α- and
obesity-induced insulin resistance,” Science, vol. 271, no.
5249, pp. 665–668, 1996.
[58] J. J. Senn, P. J. Klover, I. A. Nowak et al., “Suppressor
of cytokine signaling-3 (SOCS-3), a potential mediator of
interleukin-6-dependent insulin resistance in hepatocytes,”
Journal of Biological Chemistry, vol. 278, no. 16, pp. 13740–
13746, 2003.
[59] J. He, I. Usui, K. Ishizuka et al., “Interleukin-1α inhibits
insulin signaling with phosphorylating insulin receptor
substrate-1 on serine residues in 3T3-L1 adipocytes,” Molec-
ular Endocrinology, vol. 20, no. 1, pp. 114–124, 2006.
[60] D. Cai, M. Yuan, D. F. Frantz et al., “Local and systemic
insulin resistance resulting from hepatic activation of IKK-
β and NF-κB,” Nature Medicine, vol. 11, no. 2, pp. 183–190,
2005.
[61] J. Hirosumi, G. Tuncman, L. Chang et al., “A central, role for
JNK in obesity and insulin resistance,” Nature, vol. 420, no.
6913, pp. 333–336, 2002.
[62] C. M. Larsen, M. Faulenbach, A. Vaag et al., “Interleukin-1-
receptor antagonist in type 2 diabetes mellitus,” New England
Journal of Medicine, vol. 356, no. 15, pp. 1517–1526, 2007.
[63] M. Yuan, N. Konstantopoulos, J. Lee et al., “Reversal of
obesity- and diet-induced insulin resistance with salicylates
Mediators of Inflammation 11
or targeted disruption of Ikkβ,” Science, vol. 293, no. 5535,
pp. 1673–1677, 2001.
[64] N. S. Sauter, F. T. Schulthess, R. Galasso, L. W. Castellani, and
K. Maedler, “The antiinflammatory cytokine interleukin-
1 receptor antagonist protects from high-fat diet-induced
hyperglycemia,” Endocrinology, vol. 149, no. 5, pp. 2208–
2218, 2008.
[65] S. N. Vallerie, M. Furuhashi, R. Fucho, and G. S. Hotamisligil,
“A predominant role for parenchymal c-Jun amino terminal
kinase (JNK) in the regulation of systemic insulin sensitivity,”
PLoS ONE, vol. 3, no. 9, Article ID e3151, 2008.
[66] V. Varma, A. Yao-Borengasser, N. Rasouli et al., “Muscle
inflammatory response and insulin resistance: synergistic
interaction between macrophages and fatty acids leads to
impaired insulin action,” American Journal of Physiology, vol.
296, no. 6, pp. E1300–E1310, 2009.
[67] F. Mauvais-Jarvis, R. N. Kulkarni, and C. R. Kahn, “Knockout
models are useful tools to dissect the models of insulin resis-
tance pathophysiology and genetics of insulin resistance,”
Clinical Endocrinology, vol. 57, no. 1, pp. 1–9, 2002.
[68] E. G. Hong, J. K. Hwi, Y. R. Cho et al., “Interleukin-
10 prevents diet-induced insulin resistance by attenuating
macrophage and cytokine response in skeletal muscle,”
Diabetes, vol. 58, no. 11, pp. 2525–2535, 2009.
[69] X. Zhang, G. Zhang, H. Zhang, M. Karin, H. Bai, and
D. Cai, “Hypothalamic IKKβ/NF-κB and ER Stress Link
Overnutrition to Energy Imbalance and Obesity,” Cell, vol.
135, no. 1, pp. 61–73, 2008.
[70] A. D. Karelis, M. Brochu, and R. Rabasa-Lhoret, “Can
we identify metabolically healthy but obese individuals
(MHO)?” Diabetes and Metabolism, vol. 30, no. 6, pp. 569–
572, 2004.
[71] M. Brochu, A. Tchernof, I. J. Dionne et al., “What are the
physical characteristics associated with a normal metabolic
profile despite a high level of obesity in postmenopausal
women?” Journal of Clinical Endocrinology and Metabolism,
vol. 86, no. 3, pp. 1020–1025, 2001.
[72] E. A. H. Sims, “Are there persons who are obese, but
metabolically healthy?”Metabolism, vol. 50, no. 12, pp. 1499–
1504, 2001.
[73] N. Stefan, K. Kantartzis, J. Machann et al., “Identification and
characterization of metabolically benign obesity in humans,”
Archives of Internal Medicine, vol. 168, no. 15, pp. 1609–1616,
2008.
[74] G. Iacobellis, M. C. Ribaudo, A. Zappaterreno, C. V. Iannucci,
and F. Leonetti, “Prevalence of uncomplicated obesity in an
Italian obese population,” Obesity Research, vol. 13, no. 6, pp.
1116–1122, 2005.
[75] Y. J. Hyun, S. J. Koh, J. S. Chae et al., “Atherogenecity of LDL
and unfavorable adipokine profile in metabolically obese,
normal-weight woman,” Obesity, vol. 16, no. 4, pp. 784–789,
2008.
[76] M. J. Shin, Y. J. Hyun, O. Y. Kim, J. Y. Kim, Y. Jang,
and J. H. Lee, “Weight loss eﬀect on inflammation and
LDL oxidation in metabolically healthy but obese (MHO)
individuals: low inflammation and LDL oxidation in MHO
women,” International Journal of Obesity, vol. 30, no. 10, pp.
1529–1534, 2006.
[77] E. Succurro, M. A. Marini, S. Frontoni et al., “Insulin
secretion in metabolically obese, but normal weight, and in
metabolically healthy but obese individuals,” Obesity, vol. 16,
no. 8, pp. 1881–1886, 2008.
[78] C. A. Aguilar-Salinas, E. Garcı´a, L. Robles et al., “High adi-
ponectin concentrations are associated with the metabolical-
ly healthy obese phenotype,” Journal of Clinical Endocrinology
and Metabolism, vol. 93, no. 10, pp. 4075–4079, 2008.
[79] L. A. Lynch, J. M. O’Connell, A. K. Kwasnik, T. J. Cawood,
C. O’Farrelly, and D. B. O’Shea, “Are natural killer cells
protecting the metabolically healthy obese patient?” Obesity,
vol. 17, no. 3, pp. 601–605, 2009.
[80] A. D. Karelis, “Metabolically healthy but obese individuals,”
The Lancet, vol. 372, no. 9646, pp. 1281–1283, 2008.
[81] O. Ukkola andM. Santaniemi, “Protein tyrosine phosphatase
1B: a new target for the treatment of obesity and associated
co-morbidities,” Journal of Internal Medicine, vol. 251, no. 6,
pp. 467–475, 2002.
[82] P. A. Tataranni and E. Ortega, “A burning question: does an
adipokine-induced activation of the immune system mediate
the eﬀect of overnutrition on type 2 diabetes?” Diabetes, vol.
54, no. 4, pp. 917–927, 2005.
[83] D. R. Cottam, S. G. Mattar, E. Barinas-Mitchell et al.,
“The chronic inflammatory hypothesis for the morbidity
associated with morbid obesity: implications and eﬀect of
weight loss,” Obesity Surgery, vol. 14, no. 5, pp. 589–600,
2004.
[84] S. Virtue and A. Vidal-Puig, “Adipose tissue expandability,
lipotoxicity and the metabolic syndrome—an allostatic per-
spective,” Biochimica et Biophysica Acta, vol. 1801, no. 3, pp.
338–349, 2010.
[85] E. J. Boyko, W. Y. Fujimoto, D. L. Leonetti, and L. Newell-
Morris, “Visceral adiposity and risk of type 2 diabetes:
a prospective study among Japanese Americans,” Diabetes
Care, vol. 23, no. 4, pp. 465–471, 2000.
[86] B. H. Goodpaster, S. Krishnaswami, T. B. Harris et al.,
“Obesity, regional body fat distribution, and the metabolic
syndrome in older men and women,” Archives of Internal
Medicine, vol. 165, no. 7, pp. 777–783, 2005.
[87] S. Zhu, Z. Wang, S. Heshka, M. Heo, M. S. Faith, and S.
B. Heymsfield, “Waist circumference and obesity-associated
risk factors among whites in the third National Health and
Nutrition Examination Survey: clinical action thresholds,”
American Journal of Clinical Nutrition, vol. 76, no. 4, pp. 743–
749, 2002.
[88] C. S. Fox, J. M. Massaro, U. Hoﬀmann et al., “Abdominal
visceral and subcutaneous adipose tissue compartments:
association with metabolic risk factors in the framingham
heart study,” Circulation, vol. 116, no. 1, pp. 39–48, 2007.
[89] M. B. Snijder, J. M. Dekker, M. Visser et al., “Trunk fat and leg
fat have independent and opposite associations with fasting
and postload glucose levels. The Hoorn Study,” Diabetes
Care, vol. 27, no. 2, pp. 372–377, 2004.
[90] M. B. Snijder, M. Visser, J. M. Dekker et al., “Low subcuta-
neous thigh fat is a risk factor for unfavourable glucose and
lipid levels, independently of high abdominal fat. The Health
ABC Study,” Diabetologia, vol. 48, no. 2, pp. 301–308, 2005.
[91] S. Stenholm, A. Koster, D. E. Alley et al., “Adipocytokines and
the metabolic syndrome among older persons with and with-
out obesity. The InCHIANTI study,” Clinical Endocrinology,
vol. 73, no. 1, pp. 55–65, 2010.
[92] T. You, B. J. Nicklas, J. Ding et al., “The metabolic syndrome
is associated with circulating adipokines in older adults
across a wide range of adiposity,” Journals of Gerontology
Series A, vol. 63, no. 4, pp. 414–419, 2008.
[93] J. Hung, B. M. McQuillan, P. L. Thompson, and J. P. Beilby,
“Circulating adiponectin levels associate with inflammatory
12 Mediators of Inflammation
markers, insulin resistance and metabolic syndrome inde-
pendent of obesity,” International Journal of Obesity, vol. 32,
no. 5, pp. 772–779, 2008.
[94] L. E. Beasley, A. Koster, A. B. Newman et al., “Inflam-
mation and race and gender diﬀerences in computerized
tomography-measured adipose depots,” Obesity, vol. 17, no.
5, pp. 1062–1069, 2009.
[95] E. E. Kershaw and J. S. Flier, “Adipose tissue as an endocrine
organ,” Journal of Clinical Endocrinology and Metabolism, vol.
89, no. 6, pp. 2548–2556, 2004.
[96] B. L. Wajchenberg, “Subcutaneous and visceral adipose
tissue: their relation to the metabolic syndrome,” Endocrine
Reviews, vol. 21, no. 6, pp. 697–738, 2000.
[97] F. Wang, H. Liu, W. P. Blanton, A. Belkina, N. K. Lebrasseur,
and G. V. Denis, “Brd2 disruption in mice causes severe
obesity without Type 2 diabetes,” Biochemical Journal, vol.
425, no. 1, pp. 71–83, 2010.
[98] A. C. Belkina and G. V. Denis, “Obesity genes and insulin
resistance,” Current Opinion in Endocrinology, Diabetes and
Obesity, vol. 17, no. 5, pp. 472–477, 2010.
[99] I. Alam, A. Larbi, G. Pawelec, and P. I. Paracha, “Relationship
between anthropometric variables and nutrient intake in
apparently healthy male elderly individuals: a study from
Pakistan,” Nutrition Journal, vol. 10, pp. 111–120, 2011.
[100] H. S. Chahal and W. M. Drake, “The endocrine system and
ageing,” Journal of Pathology, vol. 211, no. 2, pp. 173–180,
2007.
[101] D. Minors, G. Atkinson, N. Bent, P. Rabbitt, and J. Water-
house, “The eﬀects of age upon some aspects of lifestyle and
implications for studies on circadian rhythmicity,” Age and
Ageing, vol. 27, no. 1, pp. 67–72, 1998.
[102] I. Alam, A. Larbi, and G. Pawelec Paracha PI, “A comparison
of anthropometrics, biochemical variables and nutrient
intake between young and elderly men,” The Journal of Aging
Research & Clinical Practice, vol. 1, no. 2, pp. 116–124, 2012.
[103] I. Alam and F. Bangash, “Oral health and nutritional status of
the free-living elderly in Peshawar, Pakistan,” Saudi Medical
Journal, vol. 31, no. 6, pp. 713–715, 2010.
[104] I. Alam, A. Larbi, and G. Pawelec, “Aging aﬀects the number
of T and B cells in a group of elderly in developing
countries—a pilot study from Pakistan,” Age. In press.
[105] I. Alam, A. Larbi, and G. Pawelec, “Nutritional status
influences peripheral immune cell phenotypes in healthy
men in rural Pakistan,” Immunity & Ageing, vol. 9, 16 pages,
2012.
[106] G. Sharma and J. Goodwin, “Eﬀect of aging on respiratory
system physiology and immunology,” Clinical Interventions
in Aging, vol. 1, no. 3, pp. 253–260, 2006.
[107] A. A. Mangoni and S. H. D. Jackson, “Age-related changes in
pharmacokinetics and pharmacodynamics: basic principles
and practical applications,” British Journal of Clinical Phar-
macology, vol. 57, no. 1, pp. 6–14, 2004.
[108] D. E. Arterburn, P. K. Crane, and S. D. Sullivan, “The coming
epidemic of obesity in elderly Americans,” Journal of the
American Geriatrics Society, vol. 52, no. 11, pp. 1907–1912,
2004.
[109] K. M. Flegal, M. D. Carroll, C. L. Ogden, and C. L. Johnson,
“Prevalence and trends in obesity among US adults, 1999-
2000,” Journal of the American Medical Association, vol. 288,
no. 14, pp. 1723–1727, 2002.
[110] J. C. Seidell, “Prevalence and time trends of obesity in
Europe,” Journal of Endocrinological Investigation, vol. 25, no.
10, pp. 816–822, 2002.
[111] J. B. Meigs, I. Lipinska, S. Kathiresan et al., “Visceral and
subcutaneous adipose tissue volumes are cross-sectionally
related to markers of inflammation and oxidative stress. The
Framingham Heart Study,” Circulation, vol. 116, no. 11, pp.
1234–1241, 2007.
[112] A. De Lorenzo, V. Del Gobbo, M. G. Premrov, M. Bigioni, F.
Galvano, and L. Di Renzo, “Normal-weight obese syndrome:
early inflammation?” American Journal of Clinical Nutrition,
vol. 85, no. 1, pp. 40–45, 2007.
[113] M. Zamboni, G. Mazzali, E. Zoico et al., “Health conse-
quences of obesity in the elderly: a review of four unresolved
questions,” International Journal of Obesity, vol. 29, no. 9, pp.
1011–1029, 2005.
[114] R. Andres, D. Elahi, and J. D. Tobin, “Impact of age on weight
goals,” Annals of Internal Medicine, vol. 103, no. 6, pp. 1030–
1033, 1985.
[115] A. Heiat, V. Vaccarino, and H. M. Krumholz, “An evidence-
based assessment of federal guidelines for overweight and
obesity as they apply to elderly persons,” Archives of Internal
Medicine, vol. 161, no. 9, pp. 1194–1203, 2001.
[116] J. C. Seidell, R. Andres, J. D. Sorkin, and D. C. Muller, “The
sagittal waist diameter and mortality in men. The Baltimore
longitudinal study on aging,” International Journal of Obesity,
vol. 18, no. 1, pp. 61–67, 1994.
[117] J. Haarbo, C. Hassager, B. J. Riis, and C. Christiansen,
“Relation of body fat distribution to serum lipids and
lipoproteins in elderly women,” Atherosclerosis, vol. 80, no.
1, pp. 57–62, 1989.
[118] A. N. Galanos, C. F. Pieper, J. C. Cornoni-Huntley, C. W.
Bales, and G. G. Fillenbaum, “Nutrition and function: is
there a relationship between body mass index and the func-
tional capabilities of community-dwelling elderly?” Journal
of the American Geriatrics Society, vol. 42, no. 4, pp. 368–373,
1994.
[119] M. C. Hochberg, M. Lethbridge-Cejku, W. W. Scott, R.
Reichle, C. C. Plato, and J. D. Tobin, “The association
of body weight, body fatness and body fat distribution
with osteoarthritis of the knee: data from the baltimore
longitudinal study of aging,” Journal of Rheumatology, vol. 22,
no. 3, pp. 488–493, 1995.
[120] D. Carmelli, G. E. Swan, and D. L. Bliwise, “Relationship of
30-year changes in obesity to sleep-disordered breathing in
the Western Collaborative Group Study,” Obesity Research,
vol. 8, no. 9, pp. 632–637, 2000.
[121] O. P. Almeida, J. Calver, K. Jamrozik, G. J. Hankey, and L.
Flicker, “Obesity andmetabolic syndrome increase the risk of
incident depression in older men: the health in men study,”
American Journal of Geriatric Psychiatry, vol. 17, no. 10, pp.
889–898, 2009.
[122] D. Gustafson, “Adiposity indices and dementia,” Lancet
Neurology, vol. 5, no. 8, pp. 713–720, 2006.
[123] A. H. Crisp and B. McGuiness, “Jolly fat: relation between
obesity and psychoneurosis in general population,” British
Medical Journal, vol. 1, no. 6000, pp. 7–9, 1976.
[124] S. Kuriyama, Y. Koizumi, K.Matsuda-Ohmori et al., “Obesity
and depressive symptoms in elderly Japanese. The Tsurugaya
Project,” Journal of Psychosomatic Research, vol. 60, no. 3, pp.
229–235, 2006.
[125] R. C. M. Ho, M. Niti, E. H. Kua, and T. P. Ng, “Body mass
index, waist circumference, waist-hip ratio and depressive
symptoms in Chinese elderly: a population-based study,”
International Journal of Geriatric Psychiatry, vol. 23, no. 4, pp.
401–408, 2008.
Mediators of Inflammation 13
[126] N. Vogelzangs, S. B. Kritchevsky, A. T. F. Beekman et
al., “Obesity and onset of significant depressive symptoms:
results from a prospective community-based cohort study of
older men and women,” Journal of Clinical Psychiatry, vol. 71,
no. 4, pp. 391–399, 2010.
[127] G. Leonarduzzi, P. Gamba, S. Gargiulo, F. Biasi, and G. Poli,
“Inflammation-related gene expression by lipid oxidation-
derived products in the progression of atherosclerosis,” Free
Radical Biology and Medicine, vol. 52, no. 1, pp. 19–34, 2012.
[128] L. Fang, S. R. Green, J. S. Baek et al., “In vivo visualization and
attenuation of oxidized lipid accumulation in hypercholes-
terolemic zebrafish,” The Journal of Clinical Investigation, vol.
121, no. 12, pp. 4861–4869, 2011.
[129] H. Mangge, G. Almer, M. Truschnig-Wilders, A. Schmidt, R.
Gasser, and D. Fuchs, “Inflammation, adiponectin, obesity
and cardiovascular risk,” Current Medicinal Chemistry, vol.
17, no. 36, pp. 4511–4520, 2010.
[130] I. Tabas, K. J. Williams, and J. Bore´n, “Subendothelial
lipoprotein retention as the initiating process in atheroscle-
rosis: update and therapeutic implications,” Circulation, vol.
116, no. 16, pp. 1832–1844, 2007.
[131] K. J. Williams and I. Tabas, “Lipoprotein retention- and clues
for atheroma regression,” Arteriosclerosis, Thrombosis, and
Vascular Biology, vol. 25, no. 8, pp. 1536–1540, 2005.
[132] K. J. Williams and I. Tabas, “The response-to-retention
hypothesis of atherogenesis reinforced,” Current Opinion in
Lipidology, vol. 9, no. 5, pp. 471–474, 1998.
[133] P. Shashkin, B. Dragulev, and K. Ley, “Macrophage diﬀeren-
tiation to foam cells,” Current Pharmaceutical Design, vol. 11,
no. 23, pp. 3061–3072, 2005.
[134] A. J. Lusis, “Atherosclerosis,” Nature, vol. 407, no. 6801, pp.
233–241, 2000.
[135] M. Rizzo, K. Berneis, E. Corrado, and S. Novo, “The signif-
icance of low-density-lipoproteins size in vascular diseases,”
International Angiology, vol. 25, no. 1, pp. 4–9, 2006.
[136] D. P. Mikhailidis, M. Elisaf, and M. Rizzo, “European panel
on low density lipoprotein (LDL) subclasses’: a statement on
the pathophysiology, atherogenicity and clinical significance
of LDL subclasses: executive summary,” Current Vascular
Pharmacology, vol. 9, pp. 531–532, 2011.
[137] M. Rizzo, E. Corrado, G. Coppola et al., “The predictive
role of C-reactive protein in patients with hypertension and
subclinical atherosclerosis,” Internal Medicine Journal, vol.
39, no. 8, pp. 539–545, 2009.
[138] K. Berneis, M. Rizzo, J. Evans, G. B. Rini, G. A. Spinas, and
J. H. Goedecke, “Interleukin-18 levels are associated with
low-density lipoproteins size,” European Journal of Clinical
Investigation, vol. 40, no. 1, pp. 54–55, 2010.
[139] M. S. V. Elkind, “Inflammatory mechanisms of stroke,”
Stroke, vol. 41, no. 10, supplement, pp. S3–S8, 2010.
[140] H. R. Superko, K. K. Berneis, P. T. Williams, M. Rizzo,
and P. D. Wood, “Gemfibrozil reduces small low-density
lipoprotein more in normolipemic subjects classified as low-
density lipoprotein pattern B compared with pattern A,”
American Journal of Cardiology, vol. 96, no. 9, pp. 1266–1272,
2005.
[141] M. Rizzo, J. Kotur-Stevuljevic, K. Berneis et al., “Atherogenic
dyslipidemia and oxidative stress: a new look,” Translational
Research, vol. 153, no. 5, pp. 217–223, 2009.
[142] K. Berneis, M. Rizzo, C. Stettler et al., “Comparative eﬀects
of rosiglitazone and pioglitazone on fasting and postprandial
low-density lipoprotein size and subclasses in patients with
Type 2 diabetes,” Expert Opinion on Pharmacotherapy, vol. 9,
no. 3, pp. 343–349, 2008.
[143] P. M. Ridker, E. Danielson, F. A. H. Fonseca et al., “Rosu-
vastatin to prevent vascular events in men and women
with elevated C-reactive protein,” New England Journal of
Medicine, vol. 359, no. 21, pp. 2195–2207, 2008.
[144] M. Rizzo and D. P. Mikhailidis, “There is more to predicting
vascular disease than just established risk factors,” Current
Pharmaceutical Design, vol. 17, pp. 3608–3610, 2011.
[145] P. Libby, P. M. Ridker, and A. Maseri, “Inflammation and
atherosclerosis,” Circulation, vol. 105, no. 9, pp. 1135–1143,
2002.
[146] E. Corrado, M. Rizzo, G. Coppola, I. Muratori, M. Carella,
and S. Novo, “Endothelial dysfunction and carotid lesions
are strong predictors of clinical events in patients with
early stages of atherosclerosis: a 24-month follow-up study,”
Coronary Artery Disease, vol. 19, no. 3, pp. 139–144, 2008.
[147] E. Corrado, M. Rizzo, I. Muratori, G. Coppola, and S.
Novo, “Association of elevated fibrinogen and C-reactive
protein levels with carotid lesions in patients with newly
diagnosed hypertension or type II diabetes,” Archives of
Medical Research, vol. 37, no. 8, pp. 1004–1009, 2006.
[148] M. Rizzo, V. Pernice, A. Frasheri et al., “Small, dense
low-density lipoproteins (LDL) are predictors of cardio -
and cerebro-vascular events in subjects with the metabolic
syndrome,” Clinical Endocrinology, vol. 70, no. 6, pp. 870–
875, 2009.
[149] N. Vrachnis, A. Augoulea, Z. Iliodromiti, I. Lambrinoudaki,
S. Sifakis, and G. Creatsas, “Previous gestational diabetes
mellitus and markers of cardiovascular risk,” International
Journal of Endocrinology, vol. 2012, Article ID 458610, 6
pages, 2012.
[150] J. B. Echouﬀo-Tcheugui and S. Dagogo-Jack, “Preventing
diabetes mellitus in developing countries,” Nature Reviews
Endocrinology, vol. 8, pp. 557–562, 2012.
[151] K. K. Nielsen, M. de Courten, and A. Kapur, “The urgent
need for universally applicable simple screening procedures
and diagnostic criteria for gestational diabetes mellitus
- lessons from projects funded by the World Diabetes
Foundation,” Global Health Action, vol. 5, Article ID 17277,
2012.
[152] G. E. Rice, S. E. Illanes, and M. D. Mitchell, “Gestational
diabetes mellitus: a positive predictor of type 2 diabetes?”
International Journal of Endocrinology, vol. 2012, Article ID
721653, 10 pages, 2012.
[153] N. Vrachnis, P. Belitsos, S. Sifakis et al., “Role of adipokines
and other inflammatory mediators in gestational diabetes
mellitus and previous gestational diabetes mellitus,” Interna-
tional Journal of Endocrinology, vol. 2012, Article ID 549748,
12 pages, 2012.
[154] C. Franceschi, M. Bonafe`, S. Valensin et al., “Inflamm-aging.
An evolutionary perspective on immunosenescence,” Annals
of the New York Academy of Sciences, vol. 908, pp. 244–254,
2000.
[155] M. De Martinis, C. Franceschi, D. Monti, and L. Ginaldi,
“Inflamm-ageing and lifelong antigenic load as major deter-
minants of ageing rate and longevity,” FEBS Letters, vol. 579,
no. 10, pp. 2035–2039, 2005.
[156] M. Barbieri, L. Ferrucci, E. Ragno et al., “Chronic inflamma-
tion and the eﬀect of IGF-I on muscle strength and power in
older persons,” American Journal of Physiology, vol. 284, no.
3, pp. E481–E487, 2003.
[157] H. Bruunsgaard, S. Ladelund, A. N. Pedersen, M. Schroll,
T. Jørgensen, and B. K. Pedersen, “Predicting death from
14 Mediators of Inflammation
tumour necrosis factor-alpha and interleukin-6 in 80-year-
old people,” Clinical and Experimental Immunology, vol. 132,
no. 1, pp. 24–31, 2003.
[158] D. Lio, L. Scola, A. Crivello et al., “Inflammation, genetics,
and longevity: further studies on the protective eﬀects inmen
of IL-10-1082 promoter SNP and its interaction with TNF-α-
308 promoter SNP,” Journal of Medical Genetics, vol. 40, no.
4, pp. 296–299, 2003.
[159] J. Falutz, “HIV infection, body composition changes and
related metabolic complications: contributing factors and
evolving management strategies,” Current Opinion in Clinical
Nutrition and Metabolic Care, vol. 14, no. 3, pp. 255–260,
2011.
[160] R. M. Peek Jr. and M. J. Blaser, “Helicobacter pylori
and gastrointestinal tract adenocarcinomas,” Nature Reviews
Cancer, vol. 2, no. 1, pp. 28–37, 2002.
[161] M. Hecker, D. Qiu, K. Marquardt, G. Bein, and H. Hackstein,
“Continuous cytomegalovirus seroconversion in a large
group of healthy blood donors,” Vox Sanguinis, vol. 86, no.
1, pp. 41–44, 2004.
[162] A. M. Simanek, J. B. Dowd, G. Pawelec, D. Melzer, A.
Dutta, and A. E. Aiello, “Seropositivity to cytomegalovirus,
inflammation, all-cause and cardiovascular disease-related
mortality in the United States,” PLoS ONE, vol. 6, no. 2,
Article ID e16103, 2011.
